Much of Zinovkin’s current research is related to the anti-inflammatory functions of ‘nuclear factor erythroid 2-related factor 2’ (Nrf2) in some human immune cells. He and his colleague Oleg A.

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Inflammation is a key driver in many pathological conditions, including respiratory diseases. NRF2 is an important natural regulator, controlling expression of antioxidant genes, and it also plays ...

Decreasing REDD1 expression protects against high glucose-induced apoptosis, oxidative stress and inflammatory injury in podocytes through regulation of the AKT/GSK-3β/Nrf2 pathway.